Survival and heart failure therapy in chronic dialysis patients with heart failure and reduced left ventricular ejection fraction: An observational retrospective study

Acta Cardiologica

Volumn 68, Issue 1, 2013, Pages 51-57

  Derthoo, David ^a   Belmans, Ann ^a   Claes, Kathleen ^a   Bammens, Bert ^a   Ciarka, Agniezka ^a   Droogné, Walter ^a   Vanhaecke, Johan ^a   van Cleemput, Johan ^a   Janssens, Stefan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dialysis; Heart failure; Mortality; Reduced left ventricular ejection fraction

Indexed keywords

BISOPROLOL; CARVEDILOL; LISINOPRIL; METOPROLOL; NEBIVOLOL; PERINDOPRIL; RAMIPRIL;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; DIALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; HEART STROKE VOLUME; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

AGED; FEMALE; HEART FAILURE; HUMANS; MALE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE;

MLCS; MLOWN;

EID: 84875623604     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/ac.68.1.2959632     Document Type: Article

References (30)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJC, Ponikowski P, Poole-Wilson PA, Strömberg A, Van Veldhuisen D, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
2. Owan TE, Hodge DE, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
3. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890.
4. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65: 2380-2389.
5. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000.
6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285.
7. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916.
8. SAS software, version 9.2 of the SAS System for Windows. Copyright © 2002 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.
9. Klein J P, Andersen PK. Regression modelling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005; 61: 223-229.
10. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
11. Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006; 48: 645-651.
12. Yamada S, Ishii H, Takahashi H, Aoyama T, Morita Y, Kasuga H, Kimura K, Ito Y, Takahashi R, Toriyama T, Yasuda Y, Hayashi M, Kamiya H, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T. Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. Clin J Am Soc Nephrol 2010; 5: 1793-1798.
13. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 (4 Suppl 3): S1-153.
14. Kalantar-Zadeh K, Regidor DL, Kovesdy C P, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 2009; 119: 671-679.
15. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914-920.
16. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011; 79: 250-257.
17. Chan CT. Cardiovascular effects of frequent intensive hemodialysis. Seminars in Dialysis 2004; 17: 99-103.
18. Stegmayr B. Ultrafiltration and dry weight -what are the cardiovascular effects? Artif Organs 2003; 27: 227-229.
19. Stack AG, Molony DA, Rahman NS, Dosekun A, Murtphy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64: 1071-1079.
20. Sens F, Schott-Pethelaz A, Labeeuw M, Colin C, Villar E; REIN Registry. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. Kidney Int 2011; 80: 970-977.
21. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardiomyopathy in dialysis patients - beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37: 407-411.
22. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PA, Golino P, Calabro R. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
23. Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999; 55: 269-277.
24. Hara Y, Hamada M, Shigematsu Y, Murakami B, Hiwada K. Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond) 2001; 101: 219-225.
25. Tangri N, Shastri S, Tighiouart T, Beck GJ, Cheung AK, Eknoyan G, Sarnak MJ. Beta-blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis 2011; 58: 939-945.
26. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, Calabrò R. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure. J Am Coll Cardiol 2010; 56: 1701-1708.
27. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol 2010; 33: 604-608.
28. Kusaba T, Tanda S, Kameyama H, Tamagaki K, Okigaki M, Hatta T, Suzaki Y, Shirayama T, Matsubara H, Sasaki S. Efficacy of biventricular pacing for dialysis-related hypotension due to idiopathic dilated cardiomyopathy. Clin Exp Nephrol 2005; 9: 255-259.
29. Charytan D, Patrick A, Liu J, Setoguchi S, Herzog C, Brookhart A, Winkelmayer W. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011; 58: 409-417.
30. Sakhuja R, Keebler M, Lai T, Gavin C, Thakur R, Bhatt D. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol 2009; 103: 735-741.